DRNA

DRNA Stock Price Falls Over 25% Pre-Market: Why It Happened

Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria

Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3

Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug (IND) Application for LY3819469

Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform

Dicerna Announces Boehringer Ingelheim's Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement